Bespak launches Syrina 2.25 auto injector
The new Syrina 2.25 is one of the most compact versions of auto-injector available today utilising the standard 2.25 mL PFS, based on Bespak’s proprietary VapourSoft technology.
Bespak has launched Syrina 2.25 at PDA Europe 2015. Moreover, Steven Kaufman, Global Business Development Lead at the company, will chair a 1-day specialized industry discussion on innovative combinational products at a workshop taking place during the renowned PDA Europe 2015 Universe of Pre-filled Syringes & Injection Devices in Vienna, Austria.
Key focus areas to be addressed at the workshop include advanced technologies in the field of self-injection devices, ranging from auto, pen, bolus and wearable-injectors through to pumps. Above all, the event will focus on how innovation in the design of combination products will help overcome industry challenges, improve compliance and enhance the patient experience.
Moreover, the discussion will focus on insights into how primary containers, such as prefilled syringes and cartridges, both in plastic and in glass form, can be effectively integrated into such devices. Overcoming challenges and implementing effective approaches for successfully taking combinational products to market also forms a significant part of the workshop’s agenda.
Leading biopharmaceutical companies and related suppliers are set to take part in the workshop and will share industry experiences and discuss the technology behind devices used in today’s growing field of combination products. Bespak has chosen this event to launch the latest addition to the Syrina product range, Syrina 2.25. This new product will highlight how flexible the technology is, directly addressing the need for higher volume and higher viscous solutions. The Syrina range of self-injection devices, which span assisted syringes with needle safety features through to fully functioning auto-injectors, all utilise Bespak’s proven VapourSoft powerpack system.
Commenting on Bespak’s involvement in chairing the workshop, Steven Kaufman commented: “We are pleased to have this opportunity to lead industry discussion on the transformational impact, for the drug delivery device sector and for patients, of innovation in the field of combinational products. Indeed, at Bespak, we are committed to the development of advanced, problem solving technology and therefore welcome this forum for sharing insights. The PDA is a great organization and provides us with an excellent forum.”
Remarking on the launch of Syrina 2.25, Steven Kaufman said: “We are also excited to unveil our newest addition to the Syrina offering. This new product will be available for exclusive demo in Vienna and to biopharmaceutical companies that would like to conduct studies to learn more about the technology first hand. We look forward to the Vienna event.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance